tradingkey.logo

Aquestive Therapeutics Inc <AQST.OQ> expected to post a loss of 14 cents a share - Earnings Preview

ReutersMar 3, 2025 9:35 PM
  • Aquestive Therapeutics Inc AQST.OQ AQST.O is expected to show a rise in quarterly revenue when it reports results on March 5 for the period ending December 31 2024

  • The Warren New Jersey-based company is expected to report a 19.0% increase in revenue to $13.083 million from $11 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Aquestive Therapeutics Inc is for a loss of 14 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $10.00​, above​ its last closing price of $2.80. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.12

-0.13

-0.13

Met

-2.6

Jun. 30 2024

-0.13

-0.12

-0.03

Beat

75.8

Mar. 31 2024

-0.08

-0.08

-0.17

Missed

-106.5​

Dec. 31 2023

-0.08

-0.08

-0.11

Missed

-37.5

​​Sep. 30 2023

-0.11

-0.11

-0.03

Beat

73.5

Jun. 30 2023

-0.12

-0.12

-0.10

Beat

15.3​

Mar. 31 2023

-0.18

-0.19

-0.12

Beat

36.5

Dec. 31 2022

-0.21

-0.23

-0.23

Met

0.3

This summary was machine generated March 3 at 21:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI